1. Home
  2. Companies
  3. OCC
  4. Material Events

Orthocell (ASX:OCC) — Material Events

ASX:OCC · 29 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 1 article Significant 27 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
27
Orthocell Hits $3M Revenue Record, Eyes US and Canada ExpansionMedium
Orthocell posts record $3M revenue in Q3 2025, expands US and Canadian market presence
2 Oct 2025 ·Quarterly Revenue Announcement ·85
Orthocell’s Remplir Achieves 81% Success in Real-World Nerve Repair StudyMedium
Orthocell's Remplir Study Shows 81% Success Rate, Boosting US Rollout and EU/UK Regulatory Plans
8 Sept 2025 ·Clinical Study Results ·85
Orthocell Launches Remplir in Canada with First Distributor AppointmentMedium
Orthocell appoints first Canadian distributor for Remplir ahead of October launch
30 Sept 2025 ·ASX Announcement ·85
Orthocell Expands Stake to Unlock Global Rights for PearlBone Bone Regeneration TechMedium
Orthocell boosts stake in Marine Biomedical to secure global rights for innovative bone regeneration product PearlBone™
20 Oct 2025 ·Equity Investment and Strategic Partnership Announcement ·85
Orthocell Expands Asian Reach with MediTime Deal in $84 Million Thai Nerve Repair MarketMedium
Orthocell appoints MediTime as exclusive Remplir distributor in Thailand's US$84 million nerve repair market
3 July 2026 ·Distribution Agreement Announcement ·85
Orthocell’s Remplir Advances Nerve-Sparing Prostate Surgery, Tackling Key ComplicationsMedium
Orthocell’s Remplir used in nerve-sparing prostate cancer surgery to reduce complications, expanding market opportunity
16 Sept 2025 ·Product Update / Clinical Development Announcement ·85
Orthocell Hits Record $13.2M FY2026 Revenue with US and Global ExpansionMedium
Orthocell posts record FY2026 revenue of AUD 13.2M with strong US and international growth, robust cash position supports expansion
13 July 2026 ·Quarterly Report ·85
Orthocell Secures $30M to Fast-Track US Rollout of Nerve Repair BreakthroughHigh
Orthocell raises $30M to accelerate US rollout and expand regenerative medicine portfolio
17 Oct 2025 ·Capital Raising ·85
Orthocell’s Remplir™ Accelerates in Prostate Surgery, Eyes $2B U.S. MarketMedium
Orthocell's Remplir™ gains traction in prostate cancer surgery; targets $2B U.S. market expansion
20 Nov 2025 ·ASX Announcement ·85
Orthocell Hits Seventh Straight Quarter of Record Revenue, US Expansion Gains TractionMedium
Orthocell reports seventh consecutive quarter of record revenue at $3.2 million, driven by US and Australian Remplir sales
6 Jan 2026 ·Quarterly Activities and Cash Flow Report ·85
Orthocell Marks Canadian Market Entry with First Remplir SalesMedium
Orthocell Achieves First Commercial Sales of Remplir™ in Canada, Expands Global Rollout
30 Apr 2026 ·Commercial Sales Announcement ·85
Orthocell Targets $750M EU-UK Nerve Repair Market with Remplir™ ApplicationMedium
Orthocell submits EU and UK regulatory application for Remplir nerve repair product, approval expected Q3 2026
15 Dec 2025 ·Regulatory Submission ·85
Orthocell Boosts Stake, Secures Rights to PearlBone™ Bone Regeneration TechMedium
Orthocell secures strategic rights to Marine Biomedical's PearlBone™ with increased equity stake
16 Jan 2026 ·ASX Announcement ·85
Orthocell Posts $3.2M Q1 Revenue with US Sales Momentum and $48M Cash ReservesMedium
Orthocell posts $3.2M Q1 revenue with US market growth and strong cash reserves
20 Apr 2026 ·Quarterly Report ·85
Orthocell Surges with $3M Revenue, Accelerates US and Canadian ExpansionMedium
Orthocell posts record $3M quarterly revenue, advances US and Canadian Remplir rollout, strengthens leadership
10 Oct 2025 ·Quarterly Report ·85
Orthocell’s Remplir Drives Seventh Straight Quarter of Record RevenueMedium
Orthocell posts record revenue, expands US and international markets, raises $30M capital
19 Jan 2026 ·Quarterly Report ·85
Orthocell’s Remplir™ Posts Near 90% Success in Expanded Nerve Repair StudyMedium
Orthocell's Remplir™ achieves 90% success rate in nerve repair study, supporting US and EU market growth
28 Apr 2026 ·Clinical Study Results ·85
Orthocell Surges with Record H1 Revenue and Rapid US ExpansionHigh
Orthocell posts record H1 FY26 revenue, advances US and international expansion, raises $30M capital
24 Feb 2026 ·Half-Year Financial Report ·85
Orthocell Advances Asian Expansion with First Remplir Surgery in Hong KongMedium
Orthocell completes first Remplir surgery in Hong Kong, expands Asian commercialisation
3 Nov 2025 ·ASX Announcement ·85
Orthocell Expands Asian Reach with Exclusive Hong Kong Distributor AppointmentMedium
Orthocell appoints exclusive Hong Kong distributor for Remplir™, advancing Asian market expansion
29 Oct 2025 ·Distributor Appointment ·85
Orthocell Gains U.S. Defence Network Approval for Remplir™ Nerve Repair DeviceMedium
Orthocell gains U.S. Department of Defence and Veterans Affairs approval for Remplir™ nerve repair device
15 Apr 2026 ·Approval Announcement ·85
Orthocell Executes First Remplir Surgery in US Military Hospital Network Post-ApprovalMedium
Orthocell completes first Remplir surgical case in U.S. DoD and VA hospitals following approval
17 Apr 2026 ·Operational Update ·85
Orthocell Surpasses 100 US Sales of Remplir™, Boosting Nerve Repair Market PresenceMedium
Orthocell Hits 100 US Unit Sales of Remplir™ Nerve Repair Product, Accelerating US Rollout
18 Dec 2025 ·ASX Announcement ·80
Orthocell Accelerates US Rollout of Remplir, Eyeing Cash Breakeven Below 1% Market ShareMedium
Orthocell advances US market rollout of Remplir with sales growth and manufacturing expansion, targeting cash breakeven at under 1% market share
2 Feb 2026 ·Operational Update ·80
Orthocell Secures Exclusive UK Distributor for $750m Remplir™ LaunchMedium
Orthocell appoints LEDA Orthopaedics as exclusive UK distributor for Remplir™ ahead of regulatory approval
10 Mar 2026 ·Distribution Agreement Announcement ·80
Orthocell Secures Full Canadian Distribution for Remplir™, First Sales ImminentMedium
Orthocell Secures Full Canadian Distribution for Remplir™, First Sales Expected This Quarter
5 Nov 2025 ·Distribution Appointment ·80
Orthocell Scores First Commercial Sales of Remplir™ in Hong Kong, Boosting Asian ExpansionMedium
Orthocell launches first commercial sales of Remplir™ in Hong Kong, advancing Asian expansion
10 Dec 2025 ·ASX Announcement ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.